Point of Care Nano-Technology, Inc.

2023 Q2 Form 10-Q Financial Statement

#000119983523000318 Filed on June 12, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2022 Q2

Balance Sheet

Concept 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.310K $100.00
YoY Change 2210.0%
Cash & Equivalents $2.312K $100.00
Short-Term Investments
Other Short-Term Assets $1.220K
YoY Change
Inventory
Prepaid Expenses $1.220K
Receivables $100.0K
Other Receivables $0.00
Total Short-Term Assets $3.532K $100.1K
YoY Change -96.47%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles $120.0K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $120.0K $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $3.532K $100.1K
Total Long-Term Assets $120.0K $0.00
Total Assets $123.5K $100.1K
YoY Change 23.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $238.3K $92.23K
YoY Change 158.37%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $238.3K $182.2K
YoY Change 30.77%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $238.3K $182.2K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $238.3K $182.2K
YoY Change 30.77%
SHAREHOLDERS EQUITY
Retained Earnings -$120.3M
YoY Change
Common Stock $420.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares 520.0K shares
Shareholders Equity -$114.8K -$82.13K
YoY Change
Total Liabilities & Shareholders Equity $123.5K $100.1K
YoY Change 23.42%

Cashflow Statement

Concept 2023 Q2 2022 Q2

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Officers Compensation
OfficersCompensation
usd
CY2022Q2 us-gaap Officers Compensation
OfficersCompensation
usd
dei Entity Central Index Key
EntityCentralIndexKey
0001504239
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--07-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2022Q3 pcnt Share Subscriptions Received
ShareSubscriptionsReceived
usd
CY2023Q2 us-gaap Treasury Stock Value
TreasuryStockValue
usd
CY2023Q2 us-gaap Revenues
Revenues
usd
us-gaap Revenues
Revenues
usd
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
usd
CY2023Q2 us-gaap Officers Compensation
OfficersCompensation
usd
CY2023Q2 pcnt Royalty Fees
RoyaltyFees
usd
pcnt Royalty Fees
RoyaltyFees
usd
us-gaap Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
usd
us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
usd
us-gaap Officers Compensation
OfficersCompensation
usd
pcnt Share Subscription Received
ShareSubscriptionReceived
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-04-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-56356
dei Entity Registrant Name
EntityRegistrantName
POINT OF CARE NANO-TECHNOLOGY, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-2830681
dei Entity Address Address Line1
EntityAddressAddressLine1
109 Ambersweet Way
dei Entity Address City Or Town
EntityAddressCityOrTown
Davenport
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33897
dei City Area Code
CityAreaCode
(732)
dei Local Phone Number
LocalPhoneNumber
723-7395
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
420621 shares
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
2312 usd
CY2022Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
3198 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1220 usd
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2917 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
3532 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
6115 usd
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
120015 usd
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
123466 usd
CY2023Q2 us-gaap Assets
Assets
123547 usd
CY2022Q3 us-gaap Assets
Assets
129581 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
238299 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
213335 usd
CY2023Q2 us-gaap Liabilities
Liabilities
238299 usd
CY2022Q3 us-gaap Liabilities
Liabilities
213335 usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1000 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1000 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1000 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1000 shares
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
1 usd
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
1 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
420621 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
420621 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
940621 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
940621 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
420 usd
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
940 usd
CY2023Q2 pcnt Share Subscriptions Received
ShareSubscriptionsReceived
20000 usd
CY2022Q3 us-gaap Treasury Stock Value
TreasuryStockValue
520 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
120191707 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
120191707 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-120326880 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-120275882 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-114752 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-83754 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
123547 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
129581 usd
CY2022Q2 us-gaap Revenues
Revenues
100000 usd
us-gaap Revenues
Revenues
100000 usd
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1150 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3451 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6457 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2472 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13813 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14828 usd
us-gaap Officers Compensation
OfficersCompensation
1 usd
CY2023Q2 us-gaap Professional Fees
ProfessionalFees
2166 usd
CY2022Q2 us-gaap Professional Fees
ProfessionalFees
13365 usd
us-gaap Professional Fees
ProfessionalFees
33734 usd
us-gaap Professional Fees
ProfessionalFees
57058 usd
CY2022Q2 pcnt Royalty Fees
RoyaltyFees
90000 usd
pcnt Royalty Fees
RoyaltyFees
90000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
9773 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
105837 usd
us-gaap Operating Expenses
OperatingExpenses
50998 usd
us-gaap Operating Expenses
OperatingExpenses
161887 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-9773 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5837 usd
us-gaap Net Income Loss
NetIncomeLoss
-50998 usd
us-gaap Net Income Loss
NetIncomeLoss
-61887 usd
CY2023Q2 pcnt Earnings Per Share Basic And Diluted1
EarningsPerShareBasicAndDiluted1
-0.01
CY2022Q2 pcnt Earnings Per Share Basic And Diluted1
EarningsPerShareBasicAndDiluted1
-0.01
pcnt Earnings Per Share Basic And Diluted1
EarningsPerShareBasicAndDiluted1
-0.05
pcnt Earnings Per Share Basic And Diluted1
EarningsPerShareBasicAndDiluted1
-0.08
CY2023Q2 pcnt Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
420621 shares
CY2022Q2 pcnt Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
632218 shares
pcnt Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
941621 shares
pcnt Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
787183 shares
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-83754 usd
pcnt Share Subscription Received
ShareSubscriptionReceived
20000 usd
us-gaap Net Income Loss
NetIncomeLoss
-50998 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-114752 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-20240 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1 usd
us-gaap Net Income Loss
NetIncomeLoss
-61887 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-82126 usd
us-gaap Net Income Loss
NetIncomeLoss
-50998 usd
us-gaap Net Income Loss
NetIncomeLoss
-61887 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3451 usd
us-gaap Officers Compensation
OfficersCompensation
1 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
24964 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
61986 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1697 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20886 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
100 usd
pcnt Share Subscription Received
ShareSubscriptionReceived
20000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-886 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
100 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3198 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2312 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_845_eus-gaap--UseOfEstimates_z1DuNCz3CO0i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zBSWfzSCO8h2">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Changes in estimates are recognized in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available to management. Actual results could differ from those estimates.</span></p>
us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease
4985 usd
CY2022 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease
1534 usd
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
120015 usd
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
123466 usd
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
pcnt License Fee To Be Paid In Common Shares
LicenseFeeToBePaidInCommonShares
125000 usd
CY2022Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
520000 shares
CY2022Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On June 8, 2022, the Company received approval from the Financial Industry Regulatory Authority to effect a 50:1 reverse split of the Company’s outstanding common stock.
pcnt License Fee To Be Paid In Common Shares
LicenseFeeToBePaidInCommonShares
125000 usd
CY2022 pcnt License Fee To Be Paid In Common Shares
LicenseFeeToBePaidInCommonShares
125000 usd
CY2022Q2 us-gaap Royalty Expense
RoyaltyExpense
90000 usd

Files In Submission

Name View Source Status
0001199835-23-000318-index-headers.html Edgar Link pending
0001199835-23-000318-index.html Edgar Link pending
0001199835-23-000318.txt Edgar Link pending
0001199835-23-000318-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pcnt-10q.htm Edgar Link pending
pcnt-20230430.xsd Edgar Link pending
pcnt-ex31.htm Edgar Link pending
pcnt-20230430_cal.xml Edgar Link unprocessable
pcnt-20230430_lab.xml Edgar Link unprocessable
pcnt-20230430_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
pcnt-20230430_pre.xml Edgar Link unprocessable
pcnt-10q_htm.xml Edgar Link completed
pcnt-ex32.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending